Navidea Biopharmaceuticals (NAVB) Stock Price Down 12%

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) shares fell 12% on Thursday . The stock traded as low as $0.18 and last traded at $0.22. 1,183,052 shares changed hands during mid-day trading, an increase of 217% from the average session volume of 373,016 shares. The stock had previously closed at $0.25.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last posted its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The firm had revenue of $0.23 million during the quarter.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by WKRB News and is owned by of WKRB News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.wkrb13.com/2018/11/11/navidea-biopharmaceuticals-navb-stock-price-down-12.html.

Navidea Biopharmaceuticals Company Profile (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

See Also: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply